AOLS (Aeolus Pharmaceuticals) LT-Debt-to-Total-Asset: 0.00 (As of Jun. 2017)


What is Aeolus Pharmaceuticals LT-Debt-to-Total-Asset?

Aeolus Pharmaceuticals AOLS LT-Debt-to-Total-Asset is 0.00 as of Jun. 2017.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aeolus Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2017 was 0.00.

Aeolus Pharmaceuticals's long-term debt to total assets ratio stayed the same from Jun. 2016 (0.00) to Jun. 2017 (0.00).

Aeolus Pharmaceuticals  (OTCPK:AOLS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aeolus Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Aeolus Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals LT-Debt-to-Total-Asset Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aeolus Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Aeolus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2016 is calculated as

LT Debt to Total Assets (A: Sep. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2016 )/Total Assets (A: Sep. 2016 )
=0/4.167
=0.00

Aeolus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2017 is calculated as

LT Debt to Total Assets (Q: Jun. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2017 )/Total Assets (Q: Jun. 2017 )
=0/0.794
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Aeolus Pharmaceuticals (AOLS) has a LT-Debt-to-Total-Asset of 0.00 as of Jun. 2017. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Aeolus Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00.
How does Aeolus Pharmaceuticals' LT-Debt-to-Total-Asset compare to RDGL and PCYN?
Aeolus Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current LT-Debt-to-Total-Asset is 0.00 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.